The AMPA receptor modulator S18986 in the prelimbic cortex enhances acquisition and retention of an odor-reward association by Yefimenko, Natalya et al.
This is a postprint version of the following article: Yefimenko, N. ; Portero-Tresserra, M. ; Martí-Nicolovius, M. ; 
Gillazo-Blanch, G. ; Vale-Martínez, A. (2013) The AMPA receptor modulator S18986 in the prelimbic cortex 
enhances acquisition and retention of an odor-reward association. Neuroscience Letters. Vol. 548, p. 105-109. 
ISSN: 0304-3940 DOI: 10.1016/j.neulet.2013.05.032 
 
 
 
 
 
 
 
The AMPA receptor modulator S18986 in the prelimbic cortex 
enhances acquisition and retention of an odor-reward association 
 
Natalya Yefimenko1 
Marta Portero-Tresserra1 
Margarita Martí-Nicolovius1 
Gemma Guillazo-Blanch1 
Anna Vale-Martínez1,2 
 
1 Departament de Psicobiologia i Metodologia de les Ciències de la Salut, 
Institut de Neurociències, 
Universitat Autònoma de Barcelona, 
Barcelona, 
Spain 
 
 
2 Corresponding author: 
Anna Vale-Martínez 
Departament de Psicobiologia i Metodologia de les Ciències de la Salut, 
Institut de Neurociències, 
Universitat Autònoma de Barcelona, 
Barcelona, 
Spain 
Telephone: 34 93 581 3260 
Fax: 34 93 581 2001 
anna.vale@uab.cat  
 
 
E-mail addresses: 
 
nyefimenko@yahoo.es  
marta.portero@uab.cat  
margarita.marti@uab.cat 
gemma.guillazo@uab.cat  
anna.vale @uab.cat 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Código de campo cambiado 
 
 
 
 
 
Código de campo cambiado 
Código de campo cambiado 
Código de campo cambiado 
2  
 
 
 
 
 
 
 
Abstract 
 
 
Systemic administration of S18986, a positive allosteric modulator of AMPA receptors, 
improves cognition. The present study further characterizes the drug’s memory-enhancing 
properties and is the first to investigate its intracerebral effects on learning and memory. The 
results showed that rats receiving a single dose of S18986 (3µg / site) into the prelimbic cortex, 
prior to olfactory discrimination acquisition, exhibited significantly shorter latencies and fewer 
errors to make the correct response, both in the acquisition and two drug-free retention tests. 
Such findings corroborate the involvement of glutamate receptors in odor-reward learning and 
confirm the role of the AMPAkine S18986 as a cognitive enhancer. 
 
Keywords: olfactory discrimination, memory facilitation, cognitive enhancer, prefrontal cortex, 
glutamate, AMPA receptors. 
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1. Introduction 
(S)-2,3-dihydro-[3,4]-cyclopentano-1,2,4-benzothiadiazine-1,1-dioxide (S18986) is a 
positive allosteric modulator of the glutamatergic AMPA receptors (AMPAR) that has recently 
been proposed as a novel cognitive enhancer [1]. The beneficial effect of S18986 on cognitive 
processes has mainly been studied with oral administration, demonstrating positive results in 
spatial memory [1,4,15], operant-delayed alternation [11], contextual serial discrimination [7], 
delayed spatial discrimination [21] and object recognition [2,12]. Intraperitoneal administration, 
which has been studied to a lesser degree, also improved social recognition [1], spatial working 
memory [22] and counteracted scopolamine-induced impairment in passive avoidance memory 
[17]. As for its cellular effects, S18986, like other positive AMPAR modulators, would seem to 
be important for synaptic plasticity underlying learning and memory as it increases long-term 
potentiation (LTP) induction and maintenance in the hippocampus [1]. Moreover, the drug 
enhances the expression of cortical and hippocampal brain-derived neurotrophic factor (BDNF) 
(for references see [1,14]), which regulates neuronal plasticity. In addition to its effects on LTP 
and BDNF expression, the cognitive-enhancing properties of S18986 may reside in its ability to 
control the release of several neurotransmitters, as it enhances acetylcholine, noradrenaline and 
dopamine in the hippocampus and/or frontal cortex [13,17]. It has been demonstrated, by means 
of in situ brain perfusion, that brain areas on which S18986 may act are the hippocampus and 
frontal cortex [6]. 
 
Nevertheless, a better understanding of S18986 actions continues to be an important issue 
as knowledge of its intracerebral targets is relatively unknown. In this context, the present study 
aimed to investigate whether intracerebral S18986 would produce a promnesiant effect, 
similarly to what has been found in the case of systemic administration. A learning model 
sensitive to manipulations of the glutamatergic receptors is the odor discrimination task (ODT), 
which entails an odor-reward association, is rapidly learned and does not involve fear or acute 
stress [19]. A frontal cortical area that has been specifically linked to ODT is the prelimbic 
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cortex (PLC) [19,20], which receives strong projections from the olfactory bulbs [23] and is rich 
in AMPAR and NMDA receptors (NMDAR). Furthermore, previous studies in the ODT 
demonstrated that infusions into the PLC of d-cycloserine (DCS), a partial agonist of the 
NMDAR, enhanced relearning [25] and reduced brain damage-induced deficits [24]. Thus, 
using the ODT, the present research further explores the role of AMPAR modulation in 
cognition by evaluating the effects of pre-training intra-PLC administration of S18986 on 
acquisition and retention. 
 
 
2. Material and Methods 
2.1. Subjects 
 
Twenty-eight male Wistar rats with an initial mean weight of 408.09 g (SD = 34.54) were 
used. All procedures were carried out in compliance with the European Community Council 
Directive for care and use of laboratory animals (86/609/ECC) and Generalitat de Catalunya 
authorization (DOGC 2450 7/8/1997, DARP protocol number 5959). For detailed descriptions 
of materials and methods see [8] and [25]. The rats were submitted to a food restriction schedule 
for five days (12 g/day, to maintain their body weight at 85% of their free-feeding weight), after 
which they performed three habituation sessions to become familiarized with the reinforcement 
and the training box. The rats were then returned to ad libitum conditions and surgery was 
carried out. 
2.2. Surgery and microinfusion 
 
The stereotaxic coordinates for the PLC were: AP: +3.5mm from bregma, ML: ±0.6mm 
from midline, and DV: −2.9mm from cranium surface [16]. The day after the 4-day recovery 
period, the rats were again food-restricted (12 g/day) for 2-3 days and submitted to an additional 
habituation session. One day after the fourth habituation, ODT acquisition training was carried 
out. Infusions of S18986 (3µg/site) or vehicle (dimethyl sulfoxide, DMSO) were administered 
(0.5µl / hemisphere for 2 minutes) ten minutes before ODT acquisition (parameters chosen 
according to a pilot study). 
2.3. Behavior 
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2.3.1. ODT 
 
ODT acquisition involved a single four-trial session in the training box (60 cm×60 
cm×40 cm), containing three sponges (8.5cm×6.5 cm×6.5 cm) located in any three of the four 
corners of the box. Chocolate rice cereal was placed into a hole in the target sponge so that the 
rat was obliged to poke its muzzle (nose-poke) to obtain the reinforcement, which was 
associated with the same odor across trials. The location of the odorized sponges (0.2 ml 
vanilla, 0.6 ml orange and 0.3 ml anise; Vahiné, Spain) within the box was changed for each 
trial according to a previously determined protocol. The inter-trial interval was 1 min and there 
was a 3 min limit, in each trial, for the rat to find and consume the reinforcement. A behavioral 
criterion eliminated rats failing to nose-poke within a 3-min period by the fourth trial of the 
acquisition session from the main analyses. Latency before a correct response (nose poke into 
the reinforced sponge) and number of errors were scored. Two different kinds of errors were 
combined: errors of commission (nose-poke into incorrect sponges) and omissions (failure to 
nose-poke after sniffing the sponge containing the target odor). Motor behavior was analyzed 
using SMART (SMART v3.0, Panlab, Spain) video tracking system, recording the mean speed 
and distance covered to reach the sponge with the target odor. Twenty-four and forty-eight 
hours after acquisition, the rats were examined in drug-free tests using the same procedure as 
during training, with the exception that the first test trial was not reinforced, to provide a direct 
measure of memory of the previous training [20]. 
2.3.2. Olfactory perception test 
 
To rule out olfactory alterations due to S18986 infusion, an additional olfactory 
perception test was conducted at the end of the experiment [5]. The test was carried out in clean 
rat cages (50 x 22 x 14 cm) and a piece of cookie (Brambly hedge, Denmark) was buried in one 
corner of the cage. Ten minutes after infusion with either S18986 or VEH, the rats were placed 
in the cage and the latency in finding the buried cookie and commence eating was timed. Upon 
completion of the behavioral tests, the rats were subjected to histological verification of 
cannulae placements following procedures explained elsewhere [8]. 
2.4. Data analysis 
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Data (latencies and errors) were submitted to a mixed analysis of variance using repeated 
measures (ANOVA; IBM SPSS Statistics v20) in which the between-factor was Group (S18986 
and VEH) and the within-factor was Session. The Session factor consisted of 3 levels (the 
average scores of the 4 trials in each session): acquisition, 24-hour test and 48-hour test. 
Ancillary analyses were performed to control several variables that could have influenced the 
main results. Firstly, changes in motivation towards the reinforcement due to the surgical 
procedure were analyzed (ANOVA) by comparing the mean latencies to eat the cereal in 
habituations three and four. Secondly, the possible effects of S18986 on olfactory perception 
were analyzed by means of ANOVA, considering Group (S18986 and VEH) as the independent 
variable and Latency in finding the buried cookie as the dependent variable. Finally, an 
ANOVA analysis of motor behavior was performed in a subset of animals (S18986, n=6; VEH, 
n=7), considering the measures Distance covered and mean Speed to reach the target sponge. P- 
values less than 0.05 were considered to be significant. 
 
3. Results 
3.1. Histology 
 
For the final sample we only considered rats with their microinjector tips in the PLC 
within the area delimited by the anterior cingulate and infralimbic cortices and in which no 
tissue damage, due to the rate or volume of the infusions, was detected (Figure 1). Incorrectly 
implanted cannulae (n=2), the existence of problems during surgery (n = 2) and failure to fulfill 
the behavioral criterion (n=5) were considered grounds for exclusion. Thus, the final sample 
was made up of 19 subjects distributed into VEH (n = 9) and S18986 (n = 10) groups. 
3.2. Behavior 
 
As depicted in Figure 2, S18986 improved the acquisition and both retention tests as it 
reduced latency and number of errors. As for latencies (Fig. 2A), the ANOVA analysis showed 
that the Group (F(1,17)= 5.721; P= 0.029) and Session (F(2,34)= 8.077; P= 0.001) factors were 
statistically significant, which was not the case for the interaction Group x Session 
(F(2,34)=0.832; P=0.444). The analysis of total errors showed a similar pattern of results (Fig. 
2B), as Group (F(1,17)= 8.116; P= 0.010) and Session (F(2,34)= 3.554; P= 0.040) proved to be 
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statistically significant, which was not the case for Group x Session (F(2,34)= 0.775; P= 0.469). 
The test comparing the latencies of habituations three and four showed that neither Group 
(F(1,17)= 5.721; P= 0.291), Session (F(1,17)= 3.961; P= 0.063) or Group x Session (F(1,17)= 1.216; 
P= 0.286) were statistically significant. There were no deficits in olfactory sensitivity as no 
statistically significant between-group differences for the latency in finding a buried cookie 
were found (F(1,17)= 1.388; P= 0.255). There were no alterations in motor behavior (Table 1) as 
no statistically significant between-group differences were found in mean Speed (F(1,11)= 0.803; 
P= 0.389) or Distance (F(1,11)= 2.461; P= 0.145) to reach the target sponge. 
4. Discussion 
The present study showed that S18986 improved an olfactory discrimination task in that 
rats receiving a single infusion in the PLC prior to acquisition displayed significantly shorter 
latencies and fewer errors than vehicle-infused rats, in all the ODT sessions (acquisition, 24h 
and 48h retention tests). Such findings cannot be attributed to alterations in olfactory perception 
or locomotor activity since S18986 infusions did not have any effect on the latency in finding a 
buried sweet-smelling cookie or the speed and distance covered to reach the rewarded odor. A 
state-dependent learning as a consequence of the prior-to-acquisition infusions can also be 
discarded as S18986 rats exhibited a better performance than vehicle rats in the drug-free 
memory tests. The current findings corroborate that the glutamatergic transmission in the PLC 
is essential for such discrimination learning based on odorous stimuli. A previous study 
demonstrated that rats infused in the PLC with the cognitive enhancer DCS (a partial agonist of 
the NMDA receptor glycine site) exhibited a significant enhancement of ODT performance, 
especially in terms of relearning [25]. Furthermore, it has recently been shown that DCS in the 
PLC attenuated parafascicular lesion-induced deficits on ODT acquisition and retention [24]. 
The present results are, therefore, the first to demonstrate that the AMPAR potentiator S18986 
infused directly into the brain, specifically in the PLC, enhances learning and memory in adult 
rats and support the role of the drug as a cognitive enhancer. 
8  
 
 
 
 
 
 
 
Our findings cannot be directly compared to previous results obtained with S18986 
administration since, to our knowledge, there are no existing studies aimed at evaluating the 
effects of intracerebral infusions on behavioral tasks. However, facilitative effects on a number 
of learning paradigms have consistently been described with systemic (oral or intraperitoneal) 
administrations. Although memory-enhancing effects appeared to be stronger in episodic-like 
and spatial memory tasks in middle-aged animals (for references see [1]), they have been 
demonstrated in tasks exploring different types of memory, including procedural [17], working 
and relational/declarative [15], episodic contextual memory [7], in young [12], adult and aged 
rodents [15,17]. Therefore, our results, together with others, show that the beneficial effects of a 
S18986 treatment may also be extended to several kinds of memory paradigms in animals of 
different ages. 
 
 
In terms of its action mechanisms, S18986 does not interact with the glutamate binding 
site, but rather with the receptor at an allosteric site and augments the receptors’ function [3]. 
This boosts Ca2+ influx, increasing amplitude and/or duration of excitatory postsynaptic 
potentials and thus enhancing synaptic responses. Moreover, AMPAR activation exerts an 
indirect regulation of NMDAR activation (involved in synaptic plasticity mechanisms), which 
may prevent the overactivation of such receptors and reduce the excitotoxic effects related to the 
neuronal degeneration observed during ageing and age-related disorders [10]. Indeed, 
neuroprotective and neurotrophic properties of S18986 have been described [9], and it has been 
suggested that they may be involved in its prevention of age-related cognitive deficits. In 
accordance with this suggestion, a recent study has shown that systemic chronic administration 
of S18986 at low doses in aged rats increased the expression of BDNF and also enhanced 
spatial memory [4]. In addition to their effects on LTP and neurotrophic factors, memory- 
enhancing effects of AMPA allosteric modulators may lie in their capacity to modulate several 
neurotransmitter systems. Thus, S18986 enhances acetylcholine in the hippocampus of freely 
moving rats, noradrenaline in both hippocampal and frontal cortex slices, and dopamine in 
frontal cortex slices [13,17]. Such neurotransmitter release in the frontal cortex may underlie 
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memory improvement as the activation of closely related brain regions, particularly in the 
frontal cortex (PLC, infralimbic, orbital) and the amygdala, has been described specifically for 
ODT [19]. Interestingly, the involvement of noradrenaline in the PLC has been demonstrated in 
ODT consolidation [18]. Therefore, all the above data suggest that the improving effects of 
S18986 on learning and memory observed in the present experiment may be associated with the 
enhancement of synaptic plasticity mechanisms, neurotrophic factors and/or neurotransmitter 
release within the PLC neuronal networks related to ODT. 
 
 
5. Conclusions 
In summary, the present study shows that infusions of S18986, a positive allosteric 
modulator of the AMPAR, in the medial prefrontal cortex, specifically the PLC, enhanced 
learning and memory of an odor-reward task. Although direct infusions in the brain represent a 
precise way of exploring its potential benefits and effects on cognitive processes, our study is 
the first to explore the effects of intracerebral S18986. Taken as a whole, the cognitive- 
enhancing properties of S18986 demonstrated in the present rodent model of olfactory memory 
together with previous reports would indicate that S18986 may be useful in the treatment of 
memory disorders associated with age-related cognitive dysfunctions and neuropsychiatric 
conditions. We consider that additional research on the effects of S18986 infusions in other 
brain regions, such as the hippocampus, using different infusion protocols and learning 
paradigms (e.g. relational), would be necessary to further explore the neural mechanisms 
involved in its facilitative effect on memory. 
 
6. Acknowledgements 
 
 
This work was supported by funds from the Ministerio de Ciencia e Innovación 
 
(PSI2011-26862; FPI grant to MP-T: BES-2009-015395). The authors thank Mr. Gerald-Patrick 
Fannon for his support with the English-language editing. 
10  
 
 
 
 
 
 
 
7. References 
 
 
[1] K. Bernard, L. Danober, J.-Y. Thomas, C. Lebrun, C. Muñoz, A. Cordi, et al., DRUG 
FOCUS: S 18986: A positive allosteric modulator of AMPA-type glutamate receptors 
pharmacological profile of a novel cognitive enhancer, CNS Neurosci. Ther. 16 (2010) 
193-212. 
 
[2] V. Bertaina-Anglade, C.D. la Rochelle, C. Muñoz, P. Morain, K. Bernard, Comparison 
of single vs. multiple administrations of the AMPA receptors modulator S 18986 in the 
object recognition task in rats, Fundam. Clin. Pharmacol. 21 (2007) 349-54. 
 
[3] M.D. Black, Therapeutic potential of positive AMPA modulators and their relationship 
to AMPA receptor subunits. A review of preclinical data, Psychopharmacology. 179 
(2005) 154-63. 
 
[4] E.B. Bloss, R.G. Hunter, E.M. Waters, C. Munoz, K. Bernard, B.S. McEwen, Behavioral 
and biological effects of chronic S18986, a positive AMPA receptor modulator, during 
aging, Exp. Neurol. 210 (2008) 109-17.  
 
[5] N. Boix-Trelis, A. Vale-Martínez, G. Guillazo-Blanch, M. Martí-Nicolovius, Muscarinic 
cholinergic receptor blockade in the rat prelimbic cortex impairs the social transmission 
of food preference., Neurobiol. Learn. Mem. 87 (2007) 659-68. 
 
[6] F. Bourasset, K. Bernard, C. Muñoz, P. Genissel, J.M. Sherrmann, 
Neuropharmacokinetics of a new alfa-amino-3-hydroxy-5-methyl-4-isoxazole propionic 
acid (AMPA) modulator, S18986 [ S) -2,3-dihydro- [ 3,4] cyclopentano-1, 2, 4- 
benzothiadiazine-1, 1-dioxide], in the rat, , Drug Metab. Dispos. 33 (2005) 1137-1143. 
 
[7] D. Béracochéa, J.N. Philippin, S. Meunier, P. Morain, K. Bernard, Improvement of 
episodic contextual memory by S 18986 in middle-aged mice: comparison with 
donepezil, Psychopharmac. 193 (2007) 63-73. 
 
[8] A. Carballo-Márquez, P. Boadas-Vaello, I. Villarejo-Rodríguez, G. Guillazo-Blanch, M. 
Martí-Nicolovius, A. Vale-Martínez, Effects of muscarinic receptor antagonism in the 
basolateral amygdala on two-way active avoidance, Exp. Brain Res. 209 (2011) 455-64. 
 
[9] E. Dicou, C.-marie Rangon, F. Guimiot, M. Spedding, P. Gressens, R. Debre, Positive 
allosteric modulators of AMPA receptors are neuroprotective against lesions induced by 
an NMDA agonist in neonatal mouse brain, Brain Res. 970 (2003) 221-225. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Con formato: Inglés (americano) 
11  
 
 
 
 
 
 
 
[10] P.T. Francis, N.R. Sims, A.W. Procter, D.M. Bowen, Cortical pyramidal neurone loss 
may cause glutamatergic hypoactivity and cognitive impairment in Alzheimer’s disease: 
investigative and therapeutic perspectives, J. Neurochem. 60 (1993) 1589-604. 
 
[11] S.J. Kelly, K. Bernard, C. Muñoz, R.C. Lawrence, J. Thacker, C. a Grillo, et al., Effects 
of the AMPA receptor modulator S 18986 on measures of cognition and oxidative stress 
in aged rats, Psychopharmacol. 202 (2009) 225-35. 
 
[12] C. Lebrun, E. Pillière, P. Lestage, Effects of S 18986-1, a novel cognitive enhancer, on 
memory performances in an object recognition task in rats, Eur. J. Pharmacol. 401 
(2000) 205-12. 
 
[13] B. Lockhart, F. Iop, M. Closier, P. Lestage, (S)-2,3-dihydro-[3,4]cyclopentano-1,2,4- 
benzothiadiazine-1,1-dioxide: (S18986-1) a positive modulator of AMPA receptors 
enhances (S) -AMPA-mediated [3 H] noradrenaline release from rat hippocampal and 
frontal cortex slices, Eur. J. Pharmacol. (2000) 145-153. 
 
[14] B.P. Lockhart, M. Rodriguez, S. Mourlevat, P. Peron, S. Catesson, N. Villain, et al., 
S18986: a positive modulator of AMPA-receptors enhances (S)-AMPA-mediated BDNF 
mRNA and protein expression in rat primary cortical neuronal cultures, Eur. J. 
Pharmacol. 561 (2007) 23-31. 
 
[15] A. Marighetto, S. Valerio, R. Jaffard, C. Mormede, C. Muñoz, K. Bernard, et al., The 
AMPA modulator S 18986 improves declarative and working memory performances in 
aged mice, Behav. Pharmacol. 19 (2008) 235-44. 
 
[16] G. Paxinos, C. Watson, The Rat Brain in Stereotaxic Coordinates, 2010. 
 
[17] S. Rosi, M.G. Giovannini, P.J. Lestage, C. Muñoz, L.D. Corte, G. Pepeu, S 18986, a 
positive modulator of AMPA receptors with cognition-enhancing properties, increases 
ACh release in the hippocampus of young and aged rat, Neurosci. Lett. 361 (2004) 120- 
3. 
 
[18] S. Tronel, M.G.P. Feenstra, S.J. Sara, Noradrenergic action in prefrontal cortex in the 
late stage of memory consolidation, Learn. Mem. 11 (2004) 453-8. 
 
[19] S. Tronel, S.J. Sara, Mapping of olfactory memory circuits: region-specific c-fos 
activation after odor-reward associative learning or after its retrieval, Learn. Mem. 9 
(2002) 105-11. 
12  
 
 
 
 
 
 
 
[20] S. Tronel, S.J. Sara, Blockade of NMDA receptors in prelimbic cortex induces an 
enduring amnesia for odor-reward associative learning, J. Neurosci. 23 (2003) 5472-6. 
 
[21] M. Vandesquille, I. Carrié, C. Louis, D. Beracochea, P. Lestage, Effects of positive 
modulators of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type 
glutamate receptors in a benzodiazepine-induced deficit of spatial discrimination in 
mice, J. Psychopharmacol. 26 (2012) 845-56. 
 
[22] M. Vandesquille, A. Krazem, C. Louis, P. Lestage, D. Béracochéa, S 18986 reverses 
spatial working memory impairments in aged mice: comparison with memantine, 
Psychopharmacol. 215 (2011) 709-20. 
 
[23] R.P. Vertes, Interactions among the medial prefrontal cortex, hippocampus and midline 
thalamus in emotional and cognitive processing in the rat, Neuroscience. 142 (2006) 1- 
20. 
 
[24] I. Villarejo-Rodríguez, P. Boadas-Vaello, M. Portero, A. Vale-Martínez, M. Martí- 
Nicolovius, G. Guillazo-Blanch, Learning deficits in an odor reward-task induced by 
parafascicular thalamic lesions are ameliorated by pretraining d-cycloserine in the 
prelimbic cortex, Behav. Brain Res. 238 (2012) 289-292. 
 
[25] I. Villarejo-Rodríguez, A. Vale-Martínez, G. Guillazo-Blanch, M. Martí-Nicolovius, D- 
cycloserine in prelimbic cortex enhances relearning of an odor-reward associative task, 
Behav. Brain Res. 213 (2010) 113-6.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Con formato: Inglés (americano) 
13  
 
 
 
 
 
 
 
Table Legend 
 
Table 1. Mean speed (cm/sec) and mean distance (cm) to reach the target odor in each ODT 
session for each group. 
14  
 
 
 
 
 
 
 
Figure legends 
 
 
Figure 1. (A) Left: Photomicrograph (2× magnification) of cresyl violet staining at the level of 
PLC showing the cannula track and the microinjector tip of a representative subject; Right: 
stereotaxic plate providing PLC location and coordinates (AP, 4.2 mm anterior to bregma). (B) 
Location of injectors within the PLC. Schematic representation of the brain at two rostro-caudal 
levels (4.2 and 4.7 mm anterior to bregma). Each asterisk represents one subject. 
 
 
Figure 2. (A) Mean latency (± SEM) and (B) mean number of errors (± SEM) in each ODT 
session for each group. The injection of DMSO (VEH) and S18986 was administered 10 
minutes before the acquisition session. 
